Abstract
Androgen deprivation therapy has been the mainstay of treatment for men with metastatic prostate cancer and now plays a more active role in the management of less advanced cancers as neoadjuvant and adjuvant treatment. Investigative uses include primary therapy for patients unsuitable for definitive therapy and as a complement to ablative procedures, brachytherapy, and chemotherapy. Intermittent androgen deprivation therapy is being considered as an alternative to continuous therapy and further evaluated as triple androgen blockade in conjunction with finasteride. Many accepted and potential management schemes incorporating hormonal therapy are increasingly employed despite indeterminate indications for use. Here, we review currently available data on the efficacy of hormonal therapy with regard to complete androgen ablation, primary, neoadjuvant, and adjuvant therapy. Additionally, we examine the usefulness of delayed versus immediate administration, intermittent androgen deprivation, and other prospective applications for hormonal therapy.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 10-18 |
| Number of pages | 9 |
| Journal | The Canadian journal of urology |
| Volume | 14 Suppl 1 |
| State | Published - Dec 2007 |
Fingerprint
ASJC Scopus subject areas
- Medicine(all)
Cite this
Managing prostate cancer : the role of hormone therapy. / Ramirez, Michelle L.; Keane, Thomas E.; Evans, Christopher P.
In: The Canadian journal of urology, Vol. 14 Suppl 1, 12.2007, p. 10-18.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Managing prostate cancer
T2 - the role of hormone therapy.
AU - Ramirez, Michelle L.
AU - Keane, Thomas E.
AU - Evans, Christopher P
PY - 2007/12
Y1 - 2007/12
N2 - Androgen deprivation therapy has been the mainstay of treatment for men with metastatic prostate cancer and now plays a more active role in the management of less advanced cancers as neoadjuvant and adjuvant treatment. Investigative uses include primary therapy for patients unsuitable for definitive therapy and as a complement to ablative procedures, brachytherapy, and chemotherapy. Intermittent androgen deprivation therapy is being considered as an alternative to continuous therapy and further evaluated as triple androgen blockade in conjunction with finasteride. Many accepted and potential management schemes incorporating hormonal therapy are increasingly employed despite indeterminate indications for use. Here, we review currently available data on the efficacy of hormonal therapy with regard to complete androgen ablation, primary, neoadjuvant, and adjuvant therapy. Additionally, we examine the usefulness of delayed versus immediate administration, intermittent androgen deprivation, and other prospective applications for hormonal therapy.
AB - Androgen deprivation therapy has been the mainstay of treatment for men with metastatic prostate cancer and now plays a more active role in the management of less advanced cancers as neoadjuvant and adjuvant treatment. Investigative uses include primary therapy for patients unsuitable for definitive therapy and as a complement to ablative procedures, brachytherapy, and chemotherapy. Intermittent androgen deprivation therapy is being considered as an alternative to continuous therapy and further evaluated as triple androgen blockade in conjunction with finasteride. Many accepted and potential management schemes incorporating hormonal therapy are increasingly employed despite indeterminate indications for use. Here, we review currently available data on the efficacy of hormonal therapy with regard to complete androgen ablation, primary, neoadjuvant, and adjuvant therapy. Additionally, we examine the usefulness of delayed versus immediate administration, intermittent androgen deprivation, and other prospective applications for hormonal therapy.
UR - http://www.scopus.com/inward/record.url?scp=40349085836&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=40349085836&partnerID=8YFLogxK
M3 - Article
VL - 14 Suppl 1
SP - 10
EP - 18
JO - Canadian Journal of Urology
JF - Canadian Journal of Urology
SN - 1195-9479
ER -